Pozvání Kliniky infekčních nemocí 1. LF UK a ÚVN do ÚVN na přednášku Dr E. Davida G. McIntoshe AM: "Reverse Vaccinology: Developing New Vaccines".


The term: 11. March 2014, from 2 p.m.

Address
Congres Centr of Military University Hospital, CH 2
U vojenské nemocnice 1200, Praha 6
GPS: +50° 5' 30.34", +14° 21' 37.20" (50.091760, 14.360332)

For: young doctors, PhD. students and medical students

Přednáška je zdarma, je pouze v anglickém jazyce, není tlumočena.

Abstract: New Frontiers in Vaccination

The pace of vaccine approvals is slowing as the targets become more difficult. There has been a "Golden Age" of innovative vaccines, for example, the polysaccharide conjugate vaccines, and the rotavirus, human papilloma virus and varicella vaccines. We are now at the dawn of the "Reverse Vaccinology Age", whereby the genetics of the organism is used to identify potential targets. One vaccine has already been licensed as a result of this: the serogroup B meningococcal vaccine. New approaches are being developed to combat the threat of pandemic influenza. And attempts are being made to target healthcare associated infections at the same time as antibiotic resistance is increasing. The lecture will cover important aspects of Reverse Vaccinology, adjuvants and vaccines targeting healthcare associated infections.

CV of  Dr E. David G. McIntosh AM
is an Australian paediatrician (with dual Australian/British nationality), vaccinologist and infectious disease specialist. Currently in Novartis Vaccines and Diagnostics he is the Global Scientific Affairs Senior Expert.
Previously, in Wyeth Pharmaceuticals, David worked on the 7- and 13-valent pneumococcal conjugate vaccines, the intra-nasal cold-adapted influenza vaccine, the antibiotics tigecycline and piperacillin-tazobactam, and the anti-parasitic agent moxidectin, under development for the treatment of River Blindness (onchocerciasis) in Africa.
He originally trained as a medical doctor in Sydney, Australia, and specialised in paediatric infectious diseases and public health. His early work was in Papua New Guinea, the Northern Territory of Australia, Peru, Argentina, New Zealand and the UK.
His early research was on early-onset Group B streptococcal infection at the King George V Hospital for Mothers and Babies in Sydney. His MPH treatise involved the study of chronic suppurative otitis media in Australian Aborigines and his PhD thesis described the molecular epidemiology of hepatitis B virus in recent immigrant families to Australia. He co-authored the landmark 50-year follow-up of the original congenital rubella syndrome patient cohort. His post-doctoral work was on gene therapy for hepatitis, in the Department of Medicine at Imperial College, a university in London, UK.
David completed a four-year Higher Medical Training period in Pharmaceutical Medicine at the Royal College of Physicians, London, and is on the Specialist Register of the UK as a Pharmaceutical Physician and as a Paediatrician. He has written chapters on hepatitis A and hepatitis B vaccination, pneumococcal vaccination, paediatric clinical pharmacology, paediatric clinical trials, post-infectious sequelae and long-term consequences of infectious diseases, efflux pumps, respiratory infections and meningococcal vaccination. In May 2012 he obtained another post-graduate degree, a Master’s degree in Medical Law and Ethics (LLM), the dissertation for which was on the subject of maternal immunisation.
David is the founder and Artistic Director of the Glebe Music Festival in Sydney, Australia, founded in 1990: www.glebemusicfestival.com
David is an Honorary Clinical Senior Lecturer at Imperial College, London, and an Honorary Professor at the Scientific Center for Children’s Health, Russian Academy of Medical Science, Moscow. On 13th June 2011 in the Queen’s Birthday Honours List he was appointed as a Member in the General Division of the Order of Australia, within the Australian Honours System. He holds the following qualifications: MBBS, MPH, LLM, PhD, FAFPHM, FRACP, FRCP&CH, FFPM, DRCOG, DCH, Dip Pharm Med.


English version
Invitation to the Military University Hospital Prague


Dr E. David G. McIntosh AM: "Reverse Vaccinology: Developing New Vaccines".

Imperial College and Novartis Vaccines

The term: 11. March 2014, from 2 p.m.

Address:
Congres Centr of Military University Hospital, CH 2
U vojenské nemocnice 1200, Praha 6
GPS: +50° 5' 30.34", +14° 21' 37.20" (50.091760, 14.360332)

For: young doctors, PhD. students and medical students

Abstract: New Frontiers in Vaccination

The pace of vaccine approvals is slowing as the targets become more difficult. There has been a "Golden Age" of innovative vaccines, for example, the polysaccharide conjugate vaccines, and the rotavirus, human papilloma virus and varicella vaccines. We are now at the dawn of the "Reverse Vaccinology Age", whereby the genetics of the organism is used to identify potential targets. One vaccine has already been licensed as a result of this: the serogroup B meningococcal vaccine. New approaches are being developed to combat the threat of pandemic influenza. And attempts are being made to target healthcare associated infections at the same time as antibiotic resistance is increasing. The lecture will cover important aspects of Reverse Vaccinology, adjuvants and vaccines targeting healthcare associated infections.

CV of  Dr E. David G. McIntosh AM
is an Australian paediatrician (with dual Australian/British nationality), vaccinologist and infectious disease specialist. Currently in Novartis Vaccines and Diagnostics he is the Global Scientific Affairs Senior Expert.
Previously, in Wyeth Pharmaceuticals, David worked on the 7- and 13-valent pneumococcal conjugate vaccines, the intra-nasal cold-adapted influenza vaccine, the antibiotics tigecycline and piperacillin-tazobactam, and the anti-parasitic agent moxidectin, under development for the treatment of River Blindness (onchocerciasis) in Africa.
He originally trained as a medical doctor in Sydney, Australia, and specialised in paediatric infectious diseases and public health. His early work was in Papua New Guinea, the Northern Territory of Australia, Peru, Argentina, New Zealand and the UK.
His early research was on early-onset Group B streptococcal infection at the King George V Hospital for Mothers and Babies in Sydney. His MPH treatise involved the study of chronic suppurative otitis media in Australian Aborigines and his PhD thesis described the molecular epidemiology of hepatitis B virus in recent immigrant families to Australia. He co-authored the landmark 50-year follow-up of the original congenital rubella syndrome patient cohort. His post-doctoral work was on gene therapy for hepatitis, in the Department of Medicine at Imperial College, a university in London, UK.
David completed a four-year Higher Medical Training period in Pharmaceutical Medicine at the Royal College of Physicians, London, and is on the Specialist Register of the UK as a Pharmaceutical Physician and as a Paediatrician. He has written chapters on hepatitis A and hepatitis B vaccination, pneumococcal vaccination, paediatric clinical pharmacology, paediatric clinical trials, post-infectious sequelae and long-term consequences of infectious diseases, efflux pumps, respiratory infections and meningococcal vaccination. In May 2012 he obtained another post-graduate degree, a Master’s degree in Medical Law and Ethics (LLM), the dissertation for which was on the subject of maternal immunisation.
David is the founder and Artistic Director of the Glebe Music Festival in Sydney, Australia, founded in 1990: www.glebemusicfestival.com
David is an Honorary Clinical Senior Lecturer at Imperial College, London, and an Honorary Professor at the Scientific Center for Children’s Health, Russian Academy of Medical Science, Moscow. On 13th June 2011 in the Queen’s Birthday Honours List he was appointed as a Member in the General Division of the Order of Australia, within the Australian Honours System. He holds the following qualifications: MBBS, MPH, LLM, PhD, FAFPHM, FRACP, FRCP&CH, FFPM, DRCOG, DCH, Dip Pharm Med.